Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Semafore Pharmaceuticals logo — Pioneering the future of cancer treatment with innovative PI...

Semafore Pharmaceuticals

Pioneering the future of cancer treatment with innovative PI3K inhibitors.

Founded 2000 Series B Total: $13.50M Biotechnology, Health Care +1

General Information

Company Name Semafore Pharmaceuticals
Founded Year 2000
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Semafore Pharmaceuticals. To contact Semafore Pharmaceuticals, visit semaforepharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Semafore Pharmaceuticals compare?

A PDF of Semafore Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Semafore Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Semafore Pharmaceuticals

Semafore Pharmaceuticals is a biotechnology company founded in 2000 with the slogan "Pioneering the future of cancer treatment with innovative PI3K inhibitors." The company focuses on developing drugs that target the PI3K cellular signaling pathways to create anti-cancer medications. Their specialized PI3K inhibitors show potential in treating tumors, holding promise for applications in cancers of the brain, lungs, and blood systems.

Notably, the company secured a $9.50M Series B investment on 08 January 2007 from Twilight Venture Partners, underscoring investor confidence in Semafore's innovative approach to cancer treatment. The company operates primarily in the biotechnology, healthcare, and pharmaceutical industries.

Business keywords: Semafore Pharmaceuticals, PI3K inhibitors, cancer treatment, drug development, cellular signaling pathways, anti-cancer medications, tumor treatment, brain cancer, lung cancer, hematological cancer, development-stage company, drug discovery, cancer research, oncology, innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $9.50M 1
Twilight Venture Partners
Twilight Venture Partners
08 Jan 2007
Grant $4.00M -
01 Jan 2006

Semafore Pharmaceuticals Alternatives & Competitors

View All Alternatives
Semafore Pharmaceuticals vs
Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. United States

Lixte Biotechnology (Nasdaq: LIXT)

Post-IPO Equity
6 employees
Biotechnology, Health Care
Semafore Pharmaceuticals vs
Advenchen Laboratories, LLC
Advenchen Laboratories, LLC

Pioneering novel therapies with promising small molecule kinase inhibitors for a brighter future in...

Venture round
6 employees
Biotechnology, Health Care
Semafore Pharmaceuticals vs
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. United States

VCP/p97 Inhibitors for Oncology and Neurodegenerative Diseases

Series C
3 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Semafore Pharmaceuticals

Pioneering the future of cancer treatment with innovative PI3K inhibitors.
Semafore Pharmaceuticals was founded in 2000.
Semafore Pharmaceuticals operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Semafore Pharmaceuticals, PI3K inhibitors, cancer treatment and drug development.
Semafore Pharmaceuticals has completed 2 funding rounds, raising a total of $13.50M. The latest funding stage is Series B.
Top alternatives and competitors to Semafore Pharmaceuticals include Lixte Biotechnology Holdings, Inc., Advenchen Laboratories, LLC, Cleave Therapeutics, Inc., Moleculin Biotech, Inc., Prescient Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Semafore Pharmaceuticals and Lixte Biotechnology Holdings, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Semafore Pharmaceuticals, https://bouncewatch.com/company/semafore-pharmaceuticals, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes